Environmental risk assessment of pharmaceuticals
4 European H2020 organizations list this as part of their work — 1 as their primary capability.
Most active in this area
- ECOLOGIC INSTITUT GEMEINNUTZIGE GMBH
Berlin-based environmental policy research centre specializing in biodiversity, nature-based solutions, circular economy, and climate governance across EU and global programmes.
“Participated in PREMIER on prioritisation and risk evaluation of medicines in the environment — a departure from their core environmental policy focus.”
SMEDE26 projects - LEUPHANA UNIVERSITAT LUNEBURG
German university specializing in sustainability science, environmental governance, social transformation, and the interface between policy, society, and environmental challenges.
“PREMIER project (2020-2026) focuses on ecotoxicology, greener drug design, environmental risk assessment, and degradation of medicines in the environment.”
DE7 projects - THE EUROPEAN MEDICINES AGENCY
EU medicines regulatory authority contributing regulatory science, pharmacovigilance, and drug approval pathway expertise to European health research consortia.
“PREMIER (2020-2026) addresses ecotoxicology, greener drug design, and environmental fate of medicines — a newer regulatory frontier for EMA.”
NL5 projects - ECT OEKOTOXIKOLOGIE GMBH
German ecotoxicology SME specializing in environmental risk assessment of pesticides and pharmaceuticals in soil ecosystems.
“In PREMIER, ECT contributes to prioritising and evaluating medicines in the environment, including degradation, sorption, and effects prediction via the fish plasma model.”
PrimarySMEDE2 projects